Vir Biotechnology (VIR) Other Accumulated Expenses (2018 - 2023)

Vir Biotechnology (VIR) has 6 years of Other Accumulated Expenses data on file, last reported at $9.7 million in Q1 2023.

• For the quarter ending Q1 2023, Other Accumulated Expenses fell 90.59% year-over-year to $9.7 million; the trailing twelve-month figure through Mar 2023 stood at $9.7 million (down 90.59% YoY), and the FY2022 full-year result was $12.7 million, up 23.96% from the prior year.
• Other Accumulated Expenses slipped to $9.7 million in Q1 2023, from $12.7 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $103.3 million in Q1 2022 to a low of $595000.0 in Q2 2020.
• A 5-year average of $13.4 million and a median of $3.3 million in 2021 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses surged 5910.47% in 2022 and slumped 90.59% in 2023, its largest moves.
• Tracing VIR's Other Accumulated Expenses over 5 years: stood at $1.2 million in 2019, then slumped by 30.36% to $805000.0 in 2020, then jumped by 1173.79% to $10.3 million in 2021, then rose by 23.96% to $12.7 million in 2022, then retreated by 23.53% to $9.7 million in 2023.
• Business Quant data shows VIR's Other Accumulated Expenses at $9.7 million in Q1 2023, $12.7 million in Q4 2022, and $27.8 million in Q3 2022.